{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:40:50Z","timestamp":1793234450883,"version":"4.5.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eat Weight Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fluoxetine remains the only pharmacological treatment approved for Bulimia Nervosa, and no other drugs have been approved for eating disorders (EDs). The rationale for exploring psilocybin as a treatment for EDs is compelling, both from biological and psychological perspectives. Moreover, its safety profile in healthy individuals appears favorable. This systematic review aims to examine original research articles and registered clinical trials to assess the current psilocybin\u2019s therapeutic potential in EDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Systematic review following the indications of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched PubMed, Excerpta Medica Database (EMBASE), and the Cochrane Library from inception until 29 July 2024, with key terms: \u201cpsilocybin\u201d and \u201ceating disorders\u201d. Quality was assessed through the\n                      <jats:italic>Quality Assessment Tool for Before\u2013After (Pre\u2013Post) Studies With No Control Group<\/jats:italic>\n                      released by the National Heart, Lung, and Blood Institute (NHLBI). We performed an additional search on the registry of clinical trials available at the website\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two studies met the inclusion criteria for our analysis. The first was an open-label feasibility study involving 10 individuals with Anorexia Nervosa (AN), without a control group. The second was a single case report describing the use of psilocybin in a person with AN. In addition, six registered clinical trials of psilocybin in individuals with EDs were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The initial evidence shows that psilocybin might be safe and well-tolerated in AN. The promising results and the need for tests in enlarged samples encourage further research on psilocybin in EDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of evidence VIII<\/jats:title>\n                    <jats:p>Evidence from nonrandomized controlled clinical trials, nonrandomized clinical trials, cohort studies, case series, case reports, and individual qualitative studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40519-025-01771-y","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T19:28:59Z","timestamp":1753817339000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Psilocybin in the treatment of eating disorders: a systematic review of the literature and registered clinical trials"],"prefix":"10.1007","volume":"30","author":[{"given":"Francesco","family":"Bevione","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carla","family":"Lacidogna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Lavalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Abbate Daga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Preti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"1771_CR1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425787","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2022","unstructured":"American Psychiatric Association (2022) Diagnostic and statistical manual of mental disorders. American Psychiatric Association Publishing, Washington"},{"key":"1771_CR2","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S0140-6736(20)30059-3","volume":"395","author":"J Treasure","year":"2020","unstructured":"Treasure J, Duarte TA, Schmidt U (2020) Eating disorders. Lancet 395:899\u2013911. https:\/\/doi.org\/10.1016\/S0140-6736(20)30059-3","journal-title":"Lancet"},{"issue":"1","key":"1771_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.74","volume":"1","author":"J Treasure","year":"2015","unstructured":"Treasure J, Zipfel S, Micali N et al (2015) Anorexia nervosa. Nat Rev Dis Primers 1(1):15074. https:\/\/doi.org\/10.1038\/nrdp.2015.74","journal-title":"Nat Rev Dis Primers"},{"key":"1771_CR4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/YCO.0000000000000739","volume":"34","author":"AE van Eeden","year":"2021","unstructured":"van Eeden AE, van Hoeken D, Hoek HW (2021) Incidence, prevalence and mortality of anorexia nervosa and bulimia nervosa. Curr Opin Psychiatry 34:515\u2013524. https:\/\/doi.org\/10.1097\/YCO.0000000000000739","journal-title":"Curr Opin Psychiatry"},{"key":"1771_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/wps.21182","volume":"23","author":"M Solmi","year":"2024","unstructured":"Solmi M, Monaco F, H\u00f8jlund M et al (2024) Outcomes in people with eating disorders: a transdiagnostic and disorder-specific systematic review, meta-analysis and multivariable meta-regression analysis. World Psychiatry 23:124\u2013138. https:\/\/doi.org\/10.1002\/wps.21182","journal-title":"World Psychiatry"},{"key":"1771_CR6","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1001\/archgenpsychiatry.2011.74","volume":"68","author":"J Arcelus","year":"2011","unstructured":"Arcelus J, Mitchell AJ, Wales J, Nielsen S (2011) Mortality rates in patients with anorexia nervosa and other eating disorders. Arch Gen Psychiatry 68:724. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2011.74","journal-title":"Arch Gen Psychiatry"},{"key":"1771_CR7","unstructured":"Istituto Superiore di Sanit\u00e0 (2024) Anoressia e Bulimia. In: https:\/\/www.epicentro.iss.it\/anoressia\/epidemiologia. https:\/\/www.epicentro.iss.it\/anoressia\/epidemiologia. Accessed 27 Jun 2024"},{"key":"1771_CR8","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/YCO.0000000000000750","volume":"34","author":"A Keski-Rahkonen","year":"2021","unstructured":"Keski-Rahkonen A (2021) Epidemiology of binge eating disorder: prevalence, course, comorbidity, and risk factors. Curr Opin Psychiatry 34:525\u2013531. https:\/\/doi.org\/10.1097\/YCO.0000000000000750","journal-title":"Curr Opin Psychiatry"},{"key":"1771_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/eat.22452","volume":"49","author":"JE Mitchell","year":"2016","unstructured":"Mitchell JE (2016) Medical comorbidity and medical complications associated with binge-eating disorder. Int J Eat Disord 49:319\u2013323. https:\/\/doi.org\/10.1002\/eat.22452","journal-title":"Int J Eat Disord"},{"key":"1771_CR10","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1016\/S0140-6736(24)00874-2","volume":"403","author":"H Himmerich","year":"2024","unstructured":"Himmerich H, Keeler JL, Davies HL et al (2024) The evolving profile of eating disorders and their treatment in a changing and globalised world. Lancet 403:2671\u20132675. https:\/\/doi.org\/10.1016\/S0140-6736(24)00874-2","journal-title":"Lancet"},{"key":"1771_CR11","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.molmed.2024.01.002","volume":"30","author":"H Himmerich","year":"2024","unstructured":"Himmerich H, Treasure J (2024) Anorexia nervosa: diagnostic, therapeutic, and risk biomarkers in clinical practice. Trends Mol Med 30:350\u2013360","journal-title":"Trends Mol Med"},{"key":"1771_CR12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/NMD.0000000000001124","volume":"208","author":"J Yager","year":"2020","unstructured":"Yager J (2020) Managing patients with severe and enduring anorexia nervosa. J Nerv Ment Dis 208:277\u2013282. https:\/\/doi.org\/10.1097\/NMD.0000000000001124","journal-title":"J Nerv Ment Dis"},{"key":"1771_CR13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.4088\/JCP.15m10393","volume":"78","author":"KT Eddy","year":"2017","unstructured":"Eddy KT, Tabri N, Thomas JJ et al (2017) Recovery from anorexia nervosa and bulimia nervosa at 22-year follow-up. J Clin Psychiatry 78:184\u2013189. https:\/\/doi.org\/10.4088\/JCP.15m10393","journal-title":"J Clin Psychiatry"},{"key":"1771_CR14","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1176\/appi.ajp.159.8.1284","volume":"159","author":"H-C Steinhausen","year":"2002","unstructured":"Steinhausen H-C (2002) The outcome of anorexia nervosa in the 20th century. Am J Psychiatry 159:1284\u20131293. https:\/\/doi.org\/10.1176\/appi.ajp.159.8.1284","journal-title":"Am J Psychiatry"},{"key":"1771_CR15","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1017\/S0033291713000949","volume":"43","author":"S Touyz","year":"2013","unstructured":"Touyz S, Le Grange D, Lacey H et al (2013) Treating severe and enduring anorexia nervosa: a randomized controlled trial. Psychol Med 43:2501\u20132511. https:\/\/doi.org\/10.1017\/S0033291713000949","journal-title":"Psychol Med"},{"key":"1771_CR16","first-page":"1","volume-title":"Eating disorders","author":"SA R\u00f6sch","year":"2023","unstructured":"R\u00f6sch SA, Hilbert A (2023) Outcome: Binge-eating disorder. Eating disorders. Springer International Publishing, Cham, pp 1\u201315"},{"key":"1771_CR17","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/978-3-031-16691-4_51","volume-title":"Eating disorders","author":"N Quadflieg","year":"2023","unstructured":"Quadflieg N (2023) Long-term outcome of inpatients and outpatients with bulimia nervosa. Eating disorders. Springer International Publishing, Cham, pp 941\u2013956"},{"key":"1771_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40337-024-01006-y","volume":"12","author":"F Marcolini","year":"2024","unstructured":"Marcolini F, Ravaglia A, Tempia Valenta S et al (2024) Severe enduring anorexia nervosa (SE-AN) treatment options and their effectiveness: a review of literature. J Eat Disord 12:48. https:\/\/doi.org\/10.1186\/s40337-024-01006-y","journal-title":"J Eat Disord"},{"key":"1771_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.116346","volume":"344","author":"P Longo","year":"2025","unstructured":"Longo P, Bevione F, Lacidogna MC et al (2025) Neuromodulatory techniques in eating disorders: from electroconvulsive therapy to transcranial magnetic stimulation and beyond: a mixed method systematic meta-review. Psychiatry Res 344:116346. https:\/\/doi.org\/10.1016\/j.psychres.2024.116346","journal-title":"Psychiatry Res"},{"key":"1771_CR20","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","volume":"79","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz MP, Ross S, Bhatt S et al (2022) Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatr 79:953\u2013962. https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.2096","journal-title":"JAMA Psychiatr"},{"key":"1771_CR21","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1227\/neu.0000000000002275","volume":"92","author":"DF Kelly","year":"2023","unstructured":"Kelly DF, Heinzerling K, Sharma A et al (2023) Psychedelic-assisted therapy and psychedelic science: a review and perspective on opportunities in neurosurgery and neuro-oncology. Neurosurgery 92:680\u2013694","journal-title":"Neurosurgery"},{"key":"1771_CR22","doi-asserted-by":"crossref","unstructured":"Ehrmann K, Allen JJB, Moreno FA (2021) Psilocybin for the treatment of obsessive-compulsive disorders. pp 247\u2013259","DOI":"10.1007\/7854_2021_279"},{"key":"1771_CR23","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O et al (2022) Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med 387:1637\u20131648. https:\/\/doi.org\/10.1056\/NEJMoa2206443","journal-title":"N Engl J Med"},{"key":"1771_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/jox12010004","volume":"12","author":"M Coppola","year":"2022","unstructured":"Coppola M, Bevione F, Mondola R (2022) Psilocybin for treating psychiatric disorders: a psychonaut legend or a promising therapeutic perspective? J Xenobiot 12:41\u201352. https:\/\/doi.org\/10.3390\/jox12010004","journal-title":"J Xenobiot"},{"key":"1771_CR25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1124\/pharmrev.120.000056","volume":"73","author":"A Inserra","year":"2021","unstructured":"Inserra A, De Gregorio D, Gobbi G (2021) Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms. Pharmacol Rev 73:202\u2013277. https:\/\/doi.org\/10.1124\/pharmrev.120.000056","journal-title":"Pharmacol Rev"},{"key":"1771_CR26","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1523\/JNEUROSCI.1659-20.2020","volume":"41","author":"D De Gregorio","year":"2021","unstructured":"De Gregorio D, Aguilar-Valles A, Preller KH et al (2021) Hallucinogens in mental health: preclinical and clinical studies on LSD, psilocybin, MDMA, and ketamine. J Neurosci 41:891\u2013900. https:\/\/doi.org\/10.1523\/JNEUROSCI.1659-20.2020","journal-title":"J Neurosci"},{"key":"1771_CR27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.physbeh.2007.11.037","volume":"94","author":"W Kaye","year":"2008","unstructured":"Kaye W (2008) Neurobiology of anorexia and bulimia nervosa. Physiol Behav 94:121\u2013135. https:\/\/doi.org\/10.1016\/j.physbeh.2007.11.037","journal-title":"Physiol Behav"},{"key":"1771_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1021\/acs.biochem.1c00812","volume":"61","author":"DE Olson","year":"2022","unstructured":"Olson DE (2022) Biochemical mechanisms underlying psychedelic-induced neuroplasticity. Biochemistry 61:127\u2013136. https:\/\/doi.org\/10.1021\/acs.biochem.1c00812","journal-title":"Biochemistry"},{"key":"1771_CR29","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.biopsych.2022.04.022","volume":"92","author":"E Walton","year":"2022","unstructured":"Walton E, Bernardoni F, Batury V-L et al (2022) Brain structure in acutely underweight and partially weight-restored individuals with anorexia nervosa: a coordinated analysis by the ENIGMA eating disorders working group. Biol Psychiatry 92:730\u2013738. https:\/\/doi.org\/10.1016\/j.biopsych.2022.04.022","journal-title":"Biol Psychiatry"},{"key":"1771_CR30","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1016\/j.cub.2021.12.009","volume":"32","author":"B Kelmendi","year":"2022","unstructured":"Kelmendi B, Kaye AP, Pittenger C, Kwan AC (2022) Psychedelics. Curr Biol 32:R63\u2013R67. https:\/\/doi.org\/10.1016\/j.cub.2021.12.009","journal-title":"Curr Biol"},{"key":"1771_CR31","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1038\/s41598-020-59282-y","volume":"10","author":"FS Barrett","year":"2020","unstructured":"Barrett FS, Doss MK, Sepeda ND et al (2020) Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep 10:2214. https:\/\/doi.org\/10.1038\/s41598-020-59282-y","journal-title":"Sci Rep"},{"key":"1771_CR32","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41386-022-01389-z","volume":"48","author":"AE Calder","year":"2023","unstructured":"Calder AE, Hasler G (2023) Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology 48:104\u2013112. https:\/\/doi.org\/10.1038\/s41386-022-01389-z","journal-title":"Neuropsychopharmacology"},{"key":"1771_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euroneuro.2023.05.008","volume":"75","author":"A Calder","year":"2023","unstructured":"Calder A, Mock S, Friedli N et al (2023) Psychedelics in the treatment of eating disorders: rationale and potential mechanisms. Eur Neuropsychopharmacol 75:1\u201314","journal-title":"Eur Neuropsychopharmacol"},{"key":"1771_CR34","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.chc.2019.05.007","volume":"28","author":"GKW Frank","year":"2019","unstructured":"Frank GKW, Shott ME, DeGuzman MC (2019) The neurobiology of eating disorders. Child Adolesc Psychiatr Clin N Am 28:629\u2013640. https:\/\/doi.org\/10.1016\/j.chc.2019.05.007","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"1771_CR35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neuroimage.2017.07.020","volume":"159","author":"CR Lewis","year":"2017","unstructured":"Lewis CR, Preller KH, Kraehenmann R et al (2017) Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. Neuroimage 159:70\u201378. https:\/\/doi.org\/10.1016\/j.neuroimage.2017.07.020","journal-title":"Neuroimage"},{"key":"1771_CR36","doi-asserted-by":"publisher","first-page":"e932","DOI":"10.1038\/tp.2016.199","volume":"6","author":"GKW Frank","year":"2016","unstructured":"Frank GKW, Shott ME, Riederer J, Pryor TL (2016) Altered structural and effective connectivity in anorexia and bulimia nervosa in circuits that regulate energy and reward homeostasis. Transl Psychiatry 6:e932\u2013e932. https:\/\/doi.org\/10.1038\/tp.2016.199","journal-title":"Transl Psychiatry"},{"key":"1771_CR37","doi-asserted-by":"publisher","first-page":"10818","DOI":"10.1038\/srep10818","volume":"5","author":"S Gaudio","year":"2015","unstructured":"Gaudio S, Piervincenzi C, Beomonte Zobel B et al (2015) Altered resting state functional connectivity of anterior cingulate cortex in drug na\u00efve adolescents at the earliest stages of anorexia nervosa. Sci Rep 5:10818. https:\/\/doi.org\/10.1038\/srep10818","journal-title":"Sci Rep"},{"key":"1771_CR38","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1038\/s41380-024-02575-9","volume":"29","author":"K Conn","year":"2024","unstructured":"Conn K, Milton LK, Huang K et al (2024) Psilocybin restrains activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms. Mol Psychiatry 29:3291\u20133304. https:\/\/doi.org\/10.1038\/s41380-024-02575-9","journal-title":"Mol Psychiatry"},{"key":"1771_CR39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fnins.2020.00043","volume":"14","author":"CJ Foldi","year":"2020","unstructured":"Foldi CJ, Liknaitzky P, Williams M, Oldfield BJ (2020) Rethinking therapeutic strategies for anorexia nervosa: insights from psychedelic medicine and animal models. Front Neurosci 14:43. https:\/\/doi.org\/10.3389\/fnins.2020.00043","journal-title":"Front Neurosci"},{"key":"1771_CR40","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.tips.2023.12.007","volume":"45","author":"F Reed","year":"2024","unstructured":"Reed F, Foldi CJ (2024) Do the therapeutic effects of psilocybin involve actions in the gut? Trends Pharmacol Sci 45:107\u2013117. https:\/\/doi.org\/10.1016\/j.tips.2023.12.007","journal-title":"Trends Pharmacol Sci"},{"key":"1771_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijchp.2022.100349","volume":"23","author":"JR Kelly","year":"2023","unstructured":"Kelly JR, Clarke G, Harkin A et al (2023) Seeking the Psilocybiome: Psychedelics meet the microbiota-gut-brain axis. Int J Clin Health Psychol 23:100349. https:\/\/doi.org\/10.1016\/j.ijchp.2022.100349","journal-title":"Int J Clin Health Psychol"},{"key":"1771_CR42","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1124\/pr.118.017160","volume":"71","author":"RL Carhart-Harris","year":"2019","unstructured":"Carhart-Harris RL, Friston KJ (2019) REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacol Rev 71:316\u2013344. https:\/\/doi.org\/10.1124\/pr.118.017160","journal-title":"Pharmacol Rev"},{"key":"1771_CR43","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.neubiorev.2019.12.006","volume":"108","author":"JT Ho","year":"2020","unstructured":"Ho JT, Preller KH, Lenggenhager B (2020) Neuropharmacological modulation of the aberrant bodily self through psychedelics. Neurosci Biobehav Rev 108:526\u2013541. https:\/\/doi.org\/10.1016\/j.neubiorev.2019.12.006","journal-title":"Neurosci Biobehav Rev"},{"key":"1771_CR44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2022489118","author":"N Hesselgrave","year":"2021","unstructured":"Hesselgrave N, Troppoli TA, Wulff AB et al (2021) Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci U S A. https:\/\/doi.org\/10.1073\/pnas.2022489118","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1771_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00782","author":"RJ Zeifman","year":"2020","unstructured":"Zeifman RJ, Wagner AC, Watts R et al (2020) Post-psychedelic reductions in experiential avoidance are associated with decreases in depression severity and suicidal ideation. Front Psychiatry. https:\/\/doi.org\/10.3389\/fpsyt.2020.00782","journal-title":"Front Psychiatry"},{"key":"1771_CR46","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/0022167817709585","volume":"57","author":"R Watts","year":"2017","unstructured":"Watts R, Day C, Krzanowski J et al (2017) Patients\u2019 accounts of increased \u201cconnectedness\u201d and \u201cacceptance\u201d after psilocybin for treatment-resistant depression. J Humanist Psychol 57:520\u2013564. https:\/\/doi.org\/10.1177\/0022167817709585","journal-title":"J Humanist Psychol"},{"key":"1771_CR47","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.euroneuro.2022.02.006","volume":"57","author":"G Hasler","year":"2022","unstructured":"Hasler G (2022) Toward the \u201chelioscope\u201d hypothesis of psychedelic therapy. Eur Neuropsychopharmacol 57:118\u2013119. https:\/\/doi.org\/10.1016\/j.euroneuro.2022.02.006","journal-title":"Eur Neuropsychopharmacol"},{"key":"1771_CR48","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J et al (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3:619\u2013627. https:\/\/doi.org\/10.1016\/S2215-0366(16)30065-7","journal-title":"Lancet Psychiatry"},{"key":"1771_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2021.113734","volume":"297","author":"M Panero","year":"2021","unstructured":"Panero M, Marzola E, Tamarin T et al (2021) Comparison between inpatients with anorexia nervosa with and without major depressive disorder: clinical characteristics and outcome. Psychiatry Res 297:113734. https:\/\/doi.org\/10.1016\/j.psychres.2021.113734","journal-title":"Psychiatry Res"},{"key":"1771_CR50","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1021\/acsmedchemlett.0c00048","volume":"11","author":"RB Kargbo","year":"2020","unstructured":"Kargbo RB (2020) Psilocybin therapeutic research: the present and future paradigm. ACS Med Chem Lett 11:399\u2013402. https:\/\/doi.org\/10.1021\/acsmedchemlett.0c00048","journal-title":"ACS Med Chem Lett"},{"key":"1771_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109467","volume":"230","author":"D Xi","year":"2023","unstructured":"Xi D, Berger A, Shurtleff D et al (2023) National institutes of health psilocybin research speaker series: state of the science, regulatory and policy landscape, research gaps, and opportunities. Neuropharmacology 230:109467. https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109467","journal-title":"Neuropharmacology"},{"key":"1771_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103473","volume":"99","author":"BS Barnett","year":"2022","unstructured":"Barnett BS, Parker SE, Weleff J (2022) United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006\u20132020. Int J Drug Policy 99:103473. https:\/\/doi.org\/10.1016\/j.drugpo.2021.103473","journal-title":"Int J Drug Policy"},{"key":"1771_CR53","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11673-022-10220-9","volume":"20","author":"LS Otterman","year":"2023","unstructured":"Otterman LS (2023) Research into psychedelic-assisted psychotherapy for anorexia nervosa should be funded. J Bioeth Inq 20:31\u201339. https:\/\/doi.org\/10.1007\/s11673-022-10220-9","journal-title":"J Bioeth Inq"},{"key":"1771_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.3869","author":"T Schwartz","year":"2021","unstructured":"Schwartz T, Trunko ME, Feifel D et al (2021) A longitudinal case series of IM ketamine for patients with severe and enduring eating disorders and comorbid treatment-resistant depression. Clin Case Rep. https:\/\/doi.org\/10.1002\/ccr3.3869","journal-title":"Clin Case Rep"},{"key":"1771_CR55","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40337-022-00588-9","volume":"10","author":"R Robison","year":"2022","unstructured":"Robison R, Lafrance A, Brendle M et al (2022) A case series of group-based ketamine-assisted psychotherapy for patients in residential treatment for eating disorders with comorbid depression and anxiety disorders. J Eat Disord 10:65. https:\/\/doi.org\/10.1186\/s40337-022-00588-9","journal-title":"J Eat Disord"},{"key":"1771_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.764112","author":"A Ragnhildstveit","year":"2021","unstructured":"Ragnhildstveit A, Jackson LK, Cunningham S et al (2021) Case report: unexpected remission from extreme and enduring bulimia nervosa with repeated ketamine assisted psychotherapy. Front Psychiatry. https:\/\/doi.org\/10.3389\/fpsyt.2021.764112","journal-title":"Front Psychiatry"},{"key":"1771_CR57","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40519-018-0619-6","volume":"25","author":"M Renelli","year":"2020","unstructured":"Renelli M, Fletcher J, Tupper KW et al (2020) An exploratory study of experiences with conventional eating disorder treatment and ceremonial ayahuasca for the healing of eating disorders. Eat Weight Disord-Stud Anorex Bulim Obes 25:437\u2013444. https:\/\/doi.org\/10.1007\/s40519-018-0619-6","journal-title":"Eat Weight Disord-Stud Anorex Bulim Obes"},{"key":"1771_CR58","doi-asserted-by":"publisher","DOI":"10.1177\/00221678211048049","author":"A Lafrance","year":"2021","unstructured":"Lafrance A, Strahan E, Bird BM et al (2021) Classic psychedelic use and mechanisms of mental health: exploring the mediating roles of spirituality and emotion processing on symptoms of anxiety, depressed mood, and disordered eating in a community sample. J Humanist Psychol. https:\/\/doi.org\/10.1177\/00221678211048049","journal-title":"J Humanist Psychol"},{"key":"1771_CR59","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"1771_CR60","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med 151:264. https:\/\/doi.org\/10.7326\/0003-4819-151-4-200908180-00135","journal-title":"Ann Intern Med"},{"key":"1771_CR61","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.amp.2021.08.004","volume":"179","author":"V Verroust","year":"2021","unstructured":"Verroust V, Zafar R, Spriggs MJ (2021) Psilocybin in the treatment of anorexia nervosa: the English transition of a French 1959 case study. Annales M\u00e9dico-psychologiques, revue psychiatrique 179:777\u2013781. https:\/\/doi.org\/10.1016\/j.amp.2021.08.004","journal-title":"Annales M\u00e9dico-psychologiques, revue psychiatrique"},{"issue":"2","key":"1771_CR62","first-page":"509","volume":"117","author":"J Delay","year":"1959","unstructured":"Delay J, Pichot P, Lemperiere T, Quetin AM (1959) Therapeutic effect of psilocybin on convulsive neurosis. Ann Med Psychol (Paris) 117(2):509\u2013515","journal-title":"Ann Med Psychol (Paris)"},{"key":"1771_CR63","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1038\/s41591-023-02455-9","volume":"29","author":"SK Peck","year":"2023","unstructured":"Peck SK, Shao S, Gruen T et al (2023) Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nat Med 29:1947\u20131953. https:\/\/doi.org\/10.1038\/s41591-023-02455-9","journal-title":"Nat Med"},{"key":"1771_CR64","unstructured":"NHLBI (2013) Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. In: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools"},{"key":"1771_CR65","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41583-020-0367-2","volume":"21","author":"FX Vollenweider","year":"2020","unstructured":"Vollenweider FX, Preller KH (2020) Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci 21:611\u2013624. https:\/\/doi.org\/10.1038\/s41583-020-0367-2","journal-title":"Nat Rev Neurosci"},{"key":"1771_CR66","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s11920-022-01394-5","volume":"24","author":"N Gukasyan","year":"2022","unstructured":"Gukasyan N, Schreyer CC, Griffiths RR, Guarda AS (2022) Psychedelic-assisted therapy for people with eating disorders. Curr Psychiatry Rep 24:767\u2013775","journal-title":"Curr Psychiatry Rep"},{"key":"1771_CR67","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cpt.2487","volume":"111","author":"AM Becker","year":"2022","unstructured":"Becker AM, Holze F, Grandinetti T et al (2022) Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects. Clin Pharmacol Ther 111:886\u2013895. https:\/\/doi.org\/10.1002\/cpt.2487","journal-title":"Clin Pharmacol Ther"},{"key":"1771_CR68","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/02698811211026454","volume":"36","author":"DE-W McCulloch","year":"2022","unstructured":"McCulloch DE-W, Madsen MK, Stenb\u00e6k DS et al (2022) Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals. J Psychopharmacol 36:74\u201384. https:\/\/doi.org\/10.1177\/02698811211026454","journal-title":"J Psychopharmacol"},{"key":"1771_CR69","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/s41398-022-02103-9","volume":"12","author":"N Fadahunsi","year":"2022","unstructured":"Fadahunsi N, Lund J, Breum AW et al (2022) Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice. Transl Psychiatry 12:330. https:\/\/doi.org\/10.1038\/s41398-022-02103-9","journal-title":"Transl Psychiatry"},{"key":"1771_CR70","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41586-024-07624-5","volume":"632","author":"JS Siegel","year":"2024","unstructured":"Siegel JS, Subramanian S, Perry D et al (2024) Psilocybin desynchronizes the human brain. Nature 632:131\u2013138. https:\/\/doi.org\/10.1038\/s41586-024-07624-5","journal-title":"Nature"},{"key":"1771_CR71","doi-asserted-by":"crossref","unstructured":"Mason NL, Szabo A, Kuypers KPC, et al (2022) Psilocybin induces acute and persisting alterations in immune status and the stress response in healthy volunteers","DOI":"10.1101\/2022.10.31.22281688"},{"key":"1771_CR72","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11920-023-01416-w","volume":"25","author":"S Gorrell","year":"2023","unstructured":"Gorrell S, Hail L, Reilly EE (2023) Predictors of treatment outcome in eating disorders: a roadmap to inform future research efforts. Curr Psychiatry Rep 25:213\u2013222. https:\/\/doi.org\/10.1007\/s11920-023-01416-w","journal-title":"Curr Psychiatry Rep"},{"key":"1771_CR73","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3390\/jcm11030542","volume":"11","author":"F Toppino","year":"2022","unstructured":"Toppino F, Longo P, Martini M et al (2022) Body mass index specifiers in anorexia nervosa: anything below the \u201cExtreme\u201d? J Clin Med 11:542. https:\/\/doi.org\/10.3390\/jcm11030542","journal-title":"J Clin Med"},{"key":"1771_CR74","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s40519-020-01000-8","volume":"26","author":"MJ Spriggs","year":"2021","unstructured":"Spriggs MJ, Kettner H, Carhart-Harris RL (2021) Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder. Eating Weight Disord Stud Anorexia, Bulimia Obesity 26:1265\u20131270. https:\/\/doi.org\/10.1007\/s40519-020-01000-8","journal-title":"Eating Weight Disord Stud Anorexia, Bulimia Obesity"},{"key":"1771_CR75","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/eat.20956","volume":"45","author":"H DeJong","year":"2012","unstructured":"DeJong H, Broadbent H, Schmidt U (2012) A systematic review of dropout from treatment in outpatients with anorexia nervosa. Int J Eat Disord 45:635\u2013647. https:\/\/doi.org\/10.1002\/eat.20956","journal-title":"Int J Eat Disord"},{"key":"1771_CR76","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S2215-0366(20)30566-6","volume":"8","author":"M Solmi","year":"2021","unstructured":"Solmi M, Wade TD, Byrne S et al (2021) Comparative efficacy and acceptability of psychological interventions for the treatment of adult outpatients with anorexia nervosa: a systematic review and network meta-analysis. Lancet Psychiatry 8:215\u2013224. https:\/\/doi.org\/10.1016\/S2215-0366(20)30566-6","journal-title":"Lancet Psychiatry"},{"key":"1771_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-9-67","volume":"9","author":"S Fassino","year":"2009","unstructured":"Fassino S, Pier\u00f2 A, Tomba E, Abbate-Daga G (2009) Factors associated with dropout from treatment for eating disorders: a comprehensive literature review. BMC Psychiatry 9:67. https:\/\/doi.org\/10.1186\/1471-244X-9-67","journal-title":"BMC Psychiatry"},{"key":"1771_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-294","volume":"13","author":"G Abbate-Daga","year":"2013","unstructured":"Abbate-Daga G, Amianto F, Delsedime N et al (2013) Resistance to treatment and change in anorexia nervosa: a clinical overview. BMC Psychiatry 13:294. https:\/\/doi.org\/10.1186\/1471-244X-13-294","journal-title":"BMC Psychiatry"},{"key":"1771_CR79","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/eat.23009","volume":"52","author":"SC Dahlenburg","year":"2019","unstructured":"Dahlenburg SC, Gleaves DH, Hutchinson AD (2019) Anorexia nervosa and perfectionism: a meta-analysis. Int J Eat Disord 52:219\u2013229","journal-title":"Int J Eat Disord"},{"key":"1771_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/cpp.2931","author":"P Longo","year":"2024","unstructured":"Longo P, Bevione F, Amodeo L et al (2024) Perfectionism in anorexia nervosa: associations with clinical picture and personality traits. Clin Psychol Psychother. https:\/\/doi.org\/10.1002\/cpp.2931","journal-title":"Clin Psychol Psychother"},{"key":"1771_CR81","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1080\/10640266.2021.1938937","volume":"30","author":"P Longo","year":"2022","unstructured":"Longo P, Aloi M, Delsedime N et al (2022) Different clusters of perfectionism in inpatients with anorexia nervosa and healthy controls. Eat Disord 30:540\u2013555. https:\/\/doi.org\/10.1080\/10640266.2021.1938937","journal-title":"Eat Disord"},{"key":"1771_CR82","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.3390\/nu16081156","volume":"16","author":"F Bevione","year":"2024","unstructured":"Bevione F, Martini M, Toppino F et al (2024) Cognitive impulsivity in anorexia nervosa in correlation with eating and obsessive symptoms: a comparison with healthy controls. Nutrients 16:1156. https:\/\/doi.org\/10.3390\/nu16081156","journal-title":"Nutrients"},{"key":"1771_CR83","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMe2210975","volume":"387","author":"BK Madras","year":"2022","unstructured":"Madras BK (2022) Psilocybin in treatment-resistant depression. N Engl J Med 387:1708\u20131709. https:\/\/doi.org\/10.1056\/NEJMe2210975","journal-title":"N Engl J Med"},{"key":"1771_CR84","doi-asserted-by":"publisher","first-page":"6683","DOI":"10.3390\/jcm11226683","volume":"11","author":"M Panero","year":"2022","unstructured":"Panero M, Longo P, De Bacco C et al (2022) Shame, guilt, and self-consciousness in anorexia nervosa. J Clin Med 11:6683. https:\/\/doi.org\/10.3390\/jcm11226683","journal-title":"J Clin Med"},{"key":"1771_CR85","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1177\/0269881120959637","volume":"35","author":"A Brouwer","year":"2021","unstructured":"Brouwer A, Carhart-Harris RL (2021) Pivotal mental states. J Psychopharmacol 35:319\u2013352. https:\/\/doi.org\/10.1177\/0269881120959637","journal-title":"J Psychopharmacol"},{"key":"1771_CR86","doi-asserted-by":"publisher","DOI":"10.1080\/20008198.2019.1682930","author":"P Longo","year":"2019","unstructured":"Longo P, Bertorello A, Panero M et al (2019) Traumatic events and post-traumatic symptoms in anorexia nervosa. Eur J Psychotraumatol. https:\/\/doi.org\/10.1080\/20008198.2019.1682930","journal-title":"Eur J Psychotraumatol"},{"key":"1771_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57010002","volume":"57","author":"P Longo","year":"2020","unstructured":"Longo P, Marzola E, De Bacco C et al (2020) Young patients with anorexia nervosa: the contribution of post-traumatic stress disorder and traumatic events. Medicina (B Aires) 57:2. https:\/\/doi.org\/10.3390\/medicina57010002","journal-title":"Medicina (B Aires)"},{"key":"1771_CR88","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/eat.23283","volume":"53","author":"SA Wonderlich","year":"2020","unstructured":"Wonderlich SA, Bulik CM, Schmidt U et al (2020) Severe and enduring anorexia nervosa: update and observations about the current clinical reality. Int J Eat Disord 53:1303\u20131312. https:\/\/doi.org\/10.1002\/eat.23283","journal-title":"Int J Eat Disord"}],"container-title":["Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40519-025-01771-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40519-025-01771-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40519-025-01771-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T14:37:28Z","timestamp":1766241448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40519-025-01771-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1771"],"URL":"https:\/\/doi.org\/10.1007\/s40519-025-01771-y","relation":{},"ISSN":["1590-1262"],"issn-type":[{"value":"1590-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,29]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}